<p>Vera Therapeutics, Inc. (NASDAQ:VERA - 获取免费报告) 的股价在周五创下 52 周新高，此前美国银行将该股的目标价从 48.00 美元上调至 66.00 美元。美国银行目前对该股维持买入评级。Vera Therapeutics 的股价最高达到 51.72 美元，最后交易价为 51.2720 美元，成交量为 751409 股。该股此前收盘价为 47.69 美元。</p>
<p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
<ul>
<li>分析师对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
<p>其他几位分析师也对该股发表了评论。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Vera Therapeutics 股票的 “卖出（d-）” 评级。Cantor Fitzgerald 在 11 月 26 日的研究报告中重申了对 Vera Therapeutics 股票的 “增持” 评级。摩根大通将 Vera Therapeutics 的目标价从 99.00 美元下调至 96.00 美元，并在周五的报告中对该公司设定了 “增持” 评级。TD Cowen 在 12 月 5 日的报告中将 Vera Therapeutics 的目标价从 60.00 美元上调至 73.00 美元，并给予该公司 “买入” 评级。最后，Pivotal Research 在 12 月 5 日的报告中对 Vera Therapeutics 设定了 73.00 美元的价格目标。十位股票研究分析师对该股给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “适度买入”，共识目标价为 74.83 美元。</p>
<p><strong>查看我们关于 VERA 的最新研究报告</strong></p>
<h2>内部买卖情况</h2>
<p>在 Vera Therapeutics 的其他消息中，高级副总裁 Joseph R. Young 在 11 月 11 日的交易中出售了 15,000 股 Vera Therapeutics 股票。该股票的平均售价为 29.06 美元，总交易额为 435,900.00 美元。出售后，该高级副总裁直接持有公司 47,839 股股票，价值 1,390,201.34 美元。此次交易使其持股减少了 23.87%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。此外，董事 Patrick G. Enright 在 12 月 11 日的交易中购买了 5,882 股 Vera Therapeutics 股票。该股票的平均购买价格为每股 42.50 美元，总交易额为 249,985.00 美元。完成购买后，该董事直接持有公司 5,882 股股票，价值 249,985 美元。此次交易使其持股增加了∞。该购买的披露信息可在 SEC 文件中找到。公司内部人士持有公司股票的 16.30%。</p>
<h2>机构资金流入和流出</h2>
<p>最近几家对冲基金买卖了 VERA 的股票。Bollard Group LLC 在第二季度以 1,509,000 美元的估值购买了 Vera Therapeutics 的新头寸。Trexquant Investment LP 在第一季度将其在 Vera Therapeutics 的持股增加了 187.1%。Trexquant Investment LP 现在拥有 62,777 股公司股票，价值 1,508,000 美元，此前在上个季度又购买了 40,913 股。Dynamic Technology Lab Private Ltd 在第一季度以约 326,000 美元的估值购买了 Vera Therapeutics 的新股份。Hudson Bay Capital Management LP 在第二季度以约 7,044,000 美元的估值收购了 Vera Therapeutics 的新股份。最后，American Century Companies Inc.在第二季度将其在 Vera Therapeutics 的持股增加了 89.3%。American Century Companies Inc.现在拥有 714,428 股公司股票，价值 16,832,000 美元，此前在该期间又购买了 336,978 股。99.21% 的股票由机构投资者和对冲基金持有。</p>
<h2>Vera Therapeutics 股票上涨 7.2%</h2>
<p>该公司的市值为 32.7 亿美元，市盈率为-12.78，贝塔值为 1.21。该公司的流动比率为 12.21，速动比率为 12.21，债务与股本比率为 0.19。该公司的 50 日移动平均价格为 33.47 美元，200 日移动平均价格为 27.17 美元。</p>
<p>Vera Therapeutics (NASDAQ:VERA - 获取免费报告) 最近在 11 月 5 日发布了季度财报。该公司报告每股收益为 (-1.26) 美元，低于市场共识预期的 (-1.20) 美元，差额为 (-0.06) 美元。在去年同期，该公司的每股收益为 (-0.85) 美元。卖方分析师预测 Vera Therapeutics, Inc.在本年度的每股收益将为-2.89 美元。</p>
<h2>Vera Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Vera Therapeutics 是一家临床阶段的生物技术公司，专注于开发新型免疫疗法，利用人体自身的调节性 T 细胞治疗自身免疫和炎症性疾病。通过利用专有的蛋白质工程平台，该公司设计了选择性针对 Treg 的细胞因子变体，旨在恢复免疫平衡并提供针对性的、具有疾病修正作用的效果。其产品管线包括多个针对慢性炎症和自身免疫特征的临床前和临床候选药物。</p>
<p>Vera Therapeutics 成立于 2018 年，总部位于马萨诸塞州剑桥市，与领先的学术和研究机构合作，推动其开发项目。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Vera Therapeutics</li>
<li>制造业股票投资</li>
<li>人工智能热潮是泡沫吗？这两只分红股票说不是</li>
<li>什么样的股票是好的分红股票？</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
<li>三只天然气股票提供优厚的分红收益</li>
<li>META 在科技下滑中上涨，分析师称特朗普的人工智能命令受到赞扬</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Vera Therapeutics 吗？</h2>
<p>在考虑 Vera Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Vera Therapeutics 并不在名单上。</p>
<p>虽然 Vera Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VERA

<p>Vera Therapeutics（纳斯达克代码：VERA）在美国银行将其目标价从 48 美元上调至 66 美元并维持买入评级后，达到了新的 52 周高点。该股最高交易价格为 51.72 美元，收盘价为 51.27 美元，较 47.69 美元上涨。分析师的评级各不相同，普遍目标价为 74.83 美元。内部交易和机构投资活跃，99.21% 的股份由机构持有。Vera Therapeutics 专注于开发针对自身免疫疾病的免疫疗法</p>

<p>Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report)'s stock price hit a new 52-week high on Friday after Bank of America raised their price target on the stock from $48.00 to $66.00. Bank of America currently has a buy rating on the stock. Vera Therapeutics traded as high as $51.72 and last traded at $51.2720, with a volume of 751409 shares. The stock had previously closed at $47.69.</p>
<div class="lb-trans"><p>Vera Therapeutics, Inc. (NASDAQ:VERA - 获取免费报告) 的股价在周五创下 52 周新高，此前美国银行将该股的目标价从 48.00 美元上调至 66.00 美元。美国银行目前对该股维持买入评级。Vera Therapeutics 的股价最高达到 51.72 美元，最后交易价为 51.2720 美元，成交量为 751409 股。该股此前收盘价为 47.69 美元。</p>
</div><p>Get <strong>Vera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
</div><p>Several other analysts have also commented on the stock. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Vera Therapeutics in a research report on Wednesday, October 8th. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. JPMorgan Chase &amp; Co. lowered their target price on shares of Vera Therapeutics from $99.00 to $96.00 and set an &#34;overweight&#34; rating for the company in a report on Friday. TD Cowen boosted their target price on Vera Therapeutics from $60.00 to $73.00 and gave the company a &#34;buy&#34; rating in a report on Friday, December 5th. Finally, Pivotal Research set a $73.00 price objective on Vera Therapeutics in a report on Friday, December 5th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $74.83.</p>
<div class="lb-trans"><p>其他几位分析师也对该股发表了评论。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Vera Therapeutics 股票的 “卖出（d-）” 评级。Cantor Fitzgerald 在 11 月 26 日的研究报告中重申了对 Vera Therapeutics 股票的 “增持” 评级。摩根大通将 Vera Therapeutics 的目标价从 99.00 美元下调至 96.00 美元，并在周五的报告中对该公司设定了 “增持” 评级。TD Cowen 在 12 月 5 日的报告中将 Vera Therapeutics 的目标价从 60.00 美元上调至 73.00 美元，并给予该公司 “买入” 评级。最后，Pivotal Research 在 12 月 5 日的报告中对 Vera Therapeutics 设定了 73.00 美元的价格目标。十位股票研究分析师对该股给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “适度买入”，共识目标价为 74.83 美元。</p>
</div><p><strong>View Our Latest Research Report on VERA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 VERA 的最新研究报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><p>In other Vera Therapeutics news, SVP Joseph R. Young sold 15,000 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the sale, the senior vice president directly owned 47,839 shares in the company, valued at $1,390,201.34. The trade was a 23.87% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, Director Patrick G. Enright acquired 5,882 shares of Vera Therapeutics stock in a transaction that occurred on Thursday, December 11th. The shares were purchased at an average price of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the purchase, the director directly owned 5,882 shares of the company's stock, valued at $249,985. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 16.30% of the company's stock.</p>
<div class="lb-trans"><p>在 Vera Therapeutics 的其他消息中，高级副总裁 Joseph R. Young 在 11 月 11 日的交易中出售了 15,000 股 Vera Therapeutics 股票。该股票的平均售价为 29.06 美元，总交易额为 435,900.00 美元。出售后，该高级副总裁直接持有公司 47,839 股股票，价值 1,390,201.34 美元。此次交易使其持股减少了 23.87%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。此外，董事 Patrick G. Enright 在 12 月 11 日的交易中购买了 5,882 股 Vera Therapeutics 股票。该股票的平均购买价格为每股 42.50 美元，总交易额为 249,985.00 美元。完成购买后，该董事直接持有公司 5,882 股股票，价值 249,985 美元。此次交易使其持股增加了∞。该购买的披露信息可在 SEC 文件中找到。公司内部人士持有公司股票的 16.30%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently bought and sold shares of VERA. Bollard Group LLC bought a new position in Vera Therapeutics in the 2nd quarter valued at $1,509,000. Trexquant Investment LP boosted its holdings in Vera Therapeutics by 187.1% during the first quarter. Trexquant Investment LP now owns 62,777 shares of the company's stock worth $1,508,000 after buying an additional 40,913 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Vera Therapeutics in the 1st quarter valued at about $326,000. Hudson Bay Capital Management LP acquired a new stake in shares of Vera Therapeutics in the 2nd quarter valued at approximately $7,044,000. Finally, American Century Companies Inc. grew its holdings in Vera Therapeutics by 89.3% during the second quarter. American Century Companies Inc. now owns 714,428 shares of the company's stock valued at $16,832,000 after purchasing an additional 336,978 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>最近几家对冲基金买卖了 VERA 的股票。Bollard Group LLC 在第二季度以 1,509,000 美元的估值购买了 Vera Therapeutics 的新头寸。Trexquant Investment LP 在第一季度将其在 Vera Therapeutics 的持股增加了 187.1%。Trexquant Investment LP 现在拥有 62,777 股公司股票，价值 1,508,000 美元，此前在上个季度又购买了 40,913 股。Dynamic Technology Lab Private Ltd 在第一季度以约 326,000 美元的估值购买了 Vera Therapeutics 的新股份。Hudson Bay Capital Management LP 在第二季度以约 7,044,000 美元的估值收购了 Vera Therapeutics 的新股份。最后，American Century Companies Inc.在第二季度将其在 Vera Therapeutics 的持股增加了 89.3%。American Century Companies Inc.现在拥有 714,428 股公司股票，价值 16,832,000 美元，此前在该期间又购买了 336,978 股。99.21% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Vera Therapeutics Stock Up 7.2%</h2>
<div class="lb-trans"><h2>Vera Therapeutics 股票上涨 7.2%</h2>
</div><p>The company has a market cap of $3.27 billion, a price-to-earnings ratio of -12.78 and a beta of 1.21. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. The firm's fifty day moving average price is $33.47 and its 200-day moving average price is $27.17.</p>
<div class="lb-trans"><p>该公司的市值为 32.7 亿美元，市盈率为-12.78，贝塔值为 1.21。该公司的流动比率为 12.21，速动比率为 12.21，债务与股本比率为 0.19。该公司的 50 日移动平均价格为 33.47 美元，200 日移动平均价格为 27.17 美元。</p>
</div><p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period in the prior year, the business earned ($0.85) earnings per share. Sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.</p>
<div class="lb-trans"><p>Vera Therapeutics (NASDAQ:VERA - 获取免费报告) 最近在 11 月 5 日发布了季度财报。该公司报告每股收益为 (-1.26) 美元，低于市场共识预期的 (-1.20) 美元，差额为 (-0.06) 美元。在去年同期，该公司的每股收益为 (-0.85) 美元。卖方分析师预测 Vera Therapeutics, Inc.在本年度的每股收益将为-2.89 美元。</p>
</div><h2>Vera Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Vera Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.</p>
<div class="lb-trans"><p>Vera Therapeutics 是一家临床阶段的生物技术公司，专注于开发新型免疫疗法，利用人体自身的调节性 T 细胞治疗自身免疫和炎症性疾病。通过利用专有的蛋白质工程平台，该公司设计了选择性针对 Treg 的细胞因子变体，旨在恢复免疫平衡并提供针对性的、具有疾病修正作用的效果。其产品管线包括多个针对慢性炎症和自身免疫特征的临床前和临床候选药物。</p>
</div><p>Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.</p>
<div class="lb-trans"><p>Vera Therapeutics 成立于 2018 年，总部位于马萨诸塞州剑桥市，与领先的学术和研究机构合作，推动其开发项目。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Vera Therapeutics</li>
<li>Manufacturing Stocks Investing</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Vera Therapeutics</li>
<li>制造业股票投资</li>
<li>人工智能热潮是泡沫吗？这两只分红股票说不是</li>
<li>什么样的股票是好的分红股票？</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
<li>三只天然气股票提供优厚的分红收益</li>
<li>META 在科技下滑中上涨，分析师称特朗普的人工智能命令受到赞扬</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Vera Therapeutics 吗？</h2>
</div><p>Before you consider Vera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vera Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Vera Therapeutics 并不在名单上。</p>
</div><p>While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vera Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Vera Therapeutics (NASDAQ:VERA) 在分析师上调评级后创下新的 12 个月高点